



BMJ is committed to ensuring the independence and integrity of our content, products, and services. We strive, therefore, to be transparent about any interests that our users, customers, and partners might want to know about.

In order to maintain its independence, DTB has a strict policy on competing interests. We need to know if authors have any financial or advisory relationship with the pharmaceutical industry or related healthcare products industry (eg, medical devices or diagnostics). This includes paid or unpaid roles and involvement with industry funded clinical trials. Declarations must cover the last three calendar years.

All authors who write articles that could influence therapeutic choices (eg, drug and treatment reviews or guidelines) must be free from conflict of interest as defined above.

Please disclose any competing interests as outlined by the International Committee of Medical Journal Editors disclosure form (below).

Author disclosure statements are published as supplementary files with articles.

Please complete the form and return it to:

dphizackerley@bmj.com

ICMJE DISCLOSURE FORM

Date: 5.12.22Your Name: Andrea Tarr

Manuscript

Title: Toxocarosis Editorial

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Please place an "X" next to the following statement to indicate your agreement:

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>None</u>	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests		Owner of Mixolydian Publications Limited, the company that publishes Veterinary Prescriber

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this

form.